Cancer Proteogenomics

Cancer Proteogenomics
Cancer Proteogenomics has emerged as the most profuse approaches in biological and medical research due to the emergence of new conceptual developments and perspectives. Proteogenomics pertains to high throughput technologies that are capable of identification and characterization of proteins by shotgun MS/MS approaches and the integration of these data with genomic data.
Proteogenomics has succeeded in discovering numerous unannotated genes and accurately defining translational start sites for many model organisms. By employing proteogenomics tools in a specific cancer, promising biomarkers could be successfully identified which could be used either for the early diagnosis or recurrence of cancer. In this session, experts will demonstrate the role of high-throughput genomic and proteomic technologies in identifying a panel of cancer biomarkers which could be used for the early diagnosis and prognosis of cancer.

Speakers


Dr. D. R. Mani
Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States

Dr. Karsten Krug
Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States

Dr. Bing Zhang
Baylor College of Medicine, Houston, Texas, United States

Dr. Karl Clauser
Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States

Dr. Debasis Dash
CSIR-Institute of Genomics and Integrative Biology, New Delhi, India